Biosensors Celebrates a Year of Achievement at TCT with Expanded Product Portfolio


October 28, 2013
stents drug eluting biosensors tct 2012 transcatheter biomatrix neoflex spectrum
October 28, 2013 — Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.
Since the 2012 Transcatheter Cardiovascular Therapeutics annual conference (TCT 2012), the company has revitalized its core offering with the launch of BioMatrix NeoFlex, a drug-eluting stent (DES) with exceptional performance in complex lesions and challenging anatomies. It also expanded its range of dedicated bifurcation stents with Axxess, which designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing a range of drug-eluting balloon dilation catheters for the treatment of both coronary and peripheral artery disease as well as introduce BioFreedom, the world’s first polymer-free stent coated with Biolimus A9.
In May, Biosensors acquired functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics’s technology is faster than conventional functional imaging, requires less contrast medium to be injected and can deliver up to 10 times the sensitivity and twice the spatial resolution.
“We have come further than we could possibly have imagined since last year’s TCT,” said Jeffrey Jump, president, cardiovascular division, Biosensors. “Over the last 12 months, we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced, so who knows what we can achieve over the next 12 months.”
For more information: